RV201 / Rivus Pharma - LARVOL DELTA

Rivus Pharmaceuticals Presents Preclinical Data for Controlled Metabolic Accelerator (CMA) Pipeline Showing Fat-Selective, Muscle-Preserving Weight Loss in Obesity at ObesityWeek (GlobeNewswire) - "Data demonstrated RV201 drives fat-selective, muscle-preserving weight loss after 8 days in a preclinical model of obesity: Weight loss: Greater weight loss for RV201 treatment groups: 16% for RV201 monotherapy; 15% (high dose) and -2% (low dose) for semaglutide monotherapy; 25% (high dose) and -22% (low dose) for semaglutide with RV201 combination therapy; After treatment stopped, weight loss was stable for 6 days for both RV201 treatment groups...RV201 monotherapy and in combination with semaglutide resulted in increased energy expenditure without increasing body temperature; Semaglutide monotherapy significantly reduced energy expenditure and food intake."

Preclinical • Obesity

Oral Controlled-Metabolic Accelerator Drives Fat-Specific Weight Loss and Augments GLP-1 Effect (OBESITY WEEK 2025) - "RV201, an oral CMA, promotes fat-specific WL in DIO mice by increasing EE and fat oxidation. Combined with SEMA, RV201 enhanced and sustained weight and fat loss, even at sub-efficacious SEMA doses, while preserving lean mass. The combination of RV201 with low-dose incretins like SEMA may provide more effective, durable WL with potentially improved tolerability vs high-dose incretin monotherapy and holds the potential for disease modification in obesity."

Genetic Disorders • Obesity